Edition:
India

Brainstorm Cell Therapuetics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.56USD
19 Jan 2018
Change (% chg)

$0.10 (+2.89%)
Prev Close
$3.46
Open
$3.51
Day's High
$3.62
Day's Low
$3.44
Volume
9,404
Avg. Vol
15,961
52-wk High
$5.15
52-wk Low
$2.57

Select another date:

Thu, Jan 4 2018

BRIEF-Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health

* BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY

BRIEF-Brainstorm Granted GMP Certification For Marketing-Level Manufacturing Of NurOwn

* BRAINSTORM GRANTED GMP CERTIFICATION FOR A MARKETING-LEVEL MANUFACTURING OF NUROWN® Source text for Eikon: Further company coverage:

BRIEF-Brainstorm Cell Therapuetics names Eyal Rubin CFO

* Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer

BRIEF-Brainstorm reports Q3 loss per share of $0.13

* Q3 loss per share $0.13 Source text for Eikon: Further company coverage:

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV, Oct 16 BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

BRIEF-Brainstorm reports Q2 loss per share of $0.06

* Q2 loss per share $0.06 Source text for Eikon: Further company coverage:

BRIEF-BrainStorm Cell Therapuetics Q2 loss per share $0.06

* Q2 loss per share $0.06 Source text for Eikon: Further company coverage:

BRIEF-Brainstorm announces agreement with University of California Irvine Medical Center

* Brainstorm announces agreement with university of california irvine medical center to participate in phase 3 trial of nurown® in als Source text for Eikon: Further company coverage:

Select another date: